LIVE 4:00 pm – 4:50 pm 4/25/2016 Winning Portfolio Strategy @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

The many considerations involved in managing a cancer portfolio are among the most important for company vitality and also play a principal role in determining the breadth and rate that new therapies reach patients. Considerations include drug categories (current or potential), use of approved drugs on new tumor types, product life extension, concentrating on call point strengths vs broadening into new cancers, technology category strength – e.g. small molecule vs emerging ones like CAR-T, product lifecycle status, competitive agents, possible portfolio swaps (e.g. NVS/GSK) and shareholder scrutiny . Panel members from the highest ranks of the industry, large and emerging companies, will discuss their strategic approach to balancing the many considerations they can influence and those that they can’t.

Moderator: Thomas Lynch, MD, CEO, Mass General Physician’s Organization, on the BOARD of BMS – declared One conflict of interest

allocation drug across indications vs per cancer type

$1Billion vs $3Billion — TRUE cost to develop a drug

innovation starts Where?

Support of internal investigators

relations with Academia is critical – at MGH it is very important Academia and Clinical

Me toos vs Blockbusters drugs?? – question from the audience

Mergers among Big Pharma – question from the audience

BioSimilars are they innovation??? – question from the audience

What will slow down innovations

Francis Cuss, MD, Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb

Optiva lung carcinoma – large population and renal – small population

immune based cancers

$100Billions goes to Drug development need to add NIH Budget

Exciting Science in 2016 like never before

set an innovation fund to find academics to solve problems

collaboration with the Community: Optiva a case in point

No interest in BioSimilars

Combination – will be the winner

worry about DISRUPTION – from Academia or Biotech

Peter Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen R&D

Immuno-oncology works on large populations trends will be to go to smaller populations

best biology the biggest benefit to patients

why cost of clinical research is going up

can we do drug development for less

Value in the marketplace in the very early stage

culture is critical How to create the culture to innovate at big Pharma

External innovations and Internal innovation very important

Mergers are spenders since they require fusion

worries me: novel, novel regimes and combination – Crisis can emerge

Briggs Morrison, MD, CEO, Syndax Pharmaceuticals – ex-Pfizer

direct cost of a successful drug with accelerated schedule of clinical trials

cost of failure

approval $300,000 from that point bringing it to the market

stochastic process for innovations and everywhere

more people work on same drug — better product

Mergers was about bringing a new product and market

Generic drugs will free investments for R&D and innovations – good for the industry as a whole

Precision medicine – is based on technology

Best in disease – if found, obsolescence is increasing

Alessandro Riva, MD, Global Head, Oncology Development and Medical Affairs, Novartis Oncology

allocation to integrate immune oncology differentiation and integration

$1 – $2Billion

Cancer Metabolism – WILL BE THE BIGGEST INNOVATION

Incubator of new ideas, deep experience – CAR-T innovation from UPenn academic link

in cancer Me too is important, though Novartis stay away from me too

it is differentiation and integration

R&D merger is there is synergy to speed up innovations

GSK and Novartis was a swap to leverage expertise in respective areas

Novartis portfolio was accelerated – it took one year, now there are advantages

Pace of innovation is fast and energizes – Prioritization – will left out some patients

Phil Rowlands, PhD, Interim Head, Oncology, Therapeutic Area Unit, Takeda

From Millenium to Takeda

Oncology will drive to smaller population types of diseases

$1.6Billion to develop a Cancer drug

what is value of BioTech – outside is brought in

co-mechanisms: myeloma

no me toos at Takeda — only what will differentiation us

BioGenerics can be smart

breakthrough are very fast, divergence across the Globe, programming streaming is harder to do